D-Matrix says its chips can run inference workloads 10 times faster and using five times less energy than a standalone graphics processing unit from Nvidia. Like Cerebras, D-Matrix is trying to prove ...

A new quantum-inspired algorithm has cracked a problem so massive that conventional supercomputers struggle to even approach it. Researchers used the method to simulate extraordinarily complex quantum ...

Apps that record visits are becoming popular, but they come with privacy and accuracy concerns. By Simar Bajaj At your next appointment, your doctor may have a new kind of assistant listening in: ...

Even if you don’t know much about the inner workings of generative AI models, you probably know they need a lot of memory. Hence, it is currently almost impossible to buy a measly stick of RAM without ...

Jake Peterson is Lifehacker’s Tech Editor, and has been covering tech news and how-tos for nearly a decade. His team covers all things technology, including AI, smartphones, computers, game consoles, ...

[Maximilian Milovidov is a freshman at Columbia University and a member of TikTok's Youth Council. He used a large language model to edit this essay for length and a human to edit for content. This ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. In a ...

I can't stand opening the Microsoft Store. It's slow to load, confusing to browse, and full of ads for things I don't care about. Luckily, thanks to a new feature, I don't have to open the Microsoft ...

I tend to divide my workday into blocks. Within minutes of waking up — we’re usually up by 5.30 a.m. — I sit down to write at least one Inc. article. Then I spend four to five hours writing a book, ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...